The combination of Ferrous Sulfate and Folic Acid is the gold standard for treating Iron Deficiency Anemia (IDA) and megaloblastic anemia. Ferrous sulfate provides the essential iron for hemoglobin synthesis, while Folic Acid is critical for DNA synthesis and red blood cell maturation.
Jiangxi Serum Pharma Industries Co., Ltd. utilizes advanced Pre-mix and Co-Crystallization technologies to ensure uniform distribution of ultra-low dose Folic Acid within the Ferrous Sulfate matrix, optimizing bio-availability and patient outcomes.
Supporting WHO initiatives to reduce maternal mortality and neonatal neural tube defects (NTDs) worldwide. Our tablets are formulated to meet international BP/USP/GMP standards, catering to both clinical and public health sectors.
Iron deficiency is the most prevalent nutritional disorder globally, affecting over 2 billion people. It is the only nutrient deficiency which is also significantly prevalent in industrialized countries. According to the World Health Organization (WHO), anemia affects 40% of pregnant women worldwide. As a leading Ferrous Sulfate Folic Acid tablet supplier, Jiangxi Serum Pharma understands that we aren't just shipping products; we are delivering life-saving interventions.
The integration of Folic Acid (Vitamin B9) into iron supplementation is not merely additive; it is synergistic. While Ferrous Sulfate addresses the heme-building blocks, Folic Acid prevents macrocytic changes in erythrocytes, which is particularly vital during the first trimester of pregnancy to prevent spina bifida and other congenital malformations.
In regions where dietary iron intake is low, our 200mg/0.4mg or customized tablets are deployed in national prenatal care programs to ensure fetal development and maternal safety during childbirth.
Addressing age-related malabsorption, our sustained-release formulations help elderly patients maintain cognitive function and energy levels without the common gastrointestinal side effects of standard iron salts.
Targeted at workers in heavy labor industries where physical exhaustion and high-turnover metabolism demand enhanced hematopoietic support.
Years Industry Experience
Global Partners
GMP-Verified Suppliers
Annual Export Value
Leveraging high-shear granulators to ensure that Folic Acid is micro-dispersed, eliminating "hot spots" in tablets and ensuring dosage uniformity within 1% of the label claim.
Moving towards fermented iron sources and natural Folic Acid variants (Methylfolate) to enhance absorption rates for patients with MTHFR gene mutations.
Integrating predictive analytics to manage raw material fluctuations in China, ensuring that even during global logistics crises, our "Best Supplier" status is maintained through inventory buffer models.
Jiangxi Serum Pharma Industries Co., Ltd. is strategically located in China's pharmaceutical heartland. This provides a three-fold advantage for global buyers:
Direct access to the world’s largest Ferrous Sulfate raw material producers ensures price stability and priority access to high-purity APIs.
Our facilities can pivot between small-batch clinical trial runs and massive national-tender quantities without compromising GMP compliance.
Proximity to major ports like Shanghai and Ningbo reduces transit times by 15-20% compared to inland suppliers.
The global iron salts market is witnessing a shift from commodity-grade generic tablets to "Value-Added" pharmaceutical services. B2B buyers no longer seek just a manufacturer; they seek a Service Provider. This includes regulatory filing support (CTD dossiers), stability testing under Zone IVb conditions (Hot/Humid), and brand customization.
Jiangxi Serum Pharma has already cooperated with partners on the customization of Pre-Mix, Co-Crystallization, and Bio-Fermentation products. This "Information Gain" approach ensures our clients stay ahead of regulatory curves in the EU, AU, and Africa markets.
A: Our tablets are tested under Zone IVb stability protocols (30°C/75% RH). We utilize PVDC/Alu packaging to ensure a minimum 3-year shelf life even in humid equatorial regions.
A: Yes. While the standard is 0.4mg or 0.5mg, we can formulate up to 5mg for therapeutic treatment of diagnosed deficiency cases, ensuring precision through our Pre-mix service.
A: We offer film-coated and enteric-coated options that delay release until the tablet reaches the duodenum, significantly reducing gastric discomfort.
